Clinical Trials
61 trialsComparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer
Radiation Therapy Oncology Group
Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer
Fox Chase Cancer Center
TROPION-Lung12
AstraZeneca
MK-7339-012
Merck Sharp & Dohme LLC
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer
National Cancer Institute (NCI)
Limertinib Plus Carboplatin and Etoposide for EGFR-mutant NSCLC With SCLC Transformation After EGFR-TKI Progression
Hunan Province Tumor Hospital
SYS6090 Combination Therapy in Advanced Lung Cancer
Shanghai JMT-Bio Inc.
Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC
Wake Forest University Health Sciences
Platinum Doublet Chemotherapy and Proton Beam Radiation Therapy in Treating Patients With Stage II-III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
Mayo Clinic
KEYVIBE-006
Merck Sharp & Dohme LLC
Hypofractionated Boost Before Chemoradiation for Patients With Stage II-III Non-small Cell Lung Cancer Unsuitable for Surgery
Ohio State University Comprehensive Cancer Center
SCope-D1
AstraZeneca
RRx-001 in Lung Cancer, Ovarian Cancer and Neuroendocrine Tumors Prior to Re-administration of Platinum Based Doublet Regimens (QUADRUPLE THREAT)
EpicentRx, Inc.
ORCHARD
AstraZeneca
First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy
Shaare Zedek Medical Center
CLOVER
AstraZeneca
Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer
Shanghai Pulmonary Hospital, Shanghai, China
M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)
EMD Serono
Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer
National Cancer Institute (NCI)
Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Neoadjuvant Chemoradiation Plus Pembrolizumab Followed By Consolidation Pembrolizumab in NSCLC
Case Comprehensive Cancer Center
MK-3475-011
Merck Sharp & Dohme LLC
Cisplatin and Etoposide Plus Radiation Followed By Nivolumab/Placebo For Locally Advanced NSCLC
RTOG Foundation, Inc.
Proton Beam Radiation Therapy and Chemotherapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Can Be Removed By Surgery
Abramson Cancer Center at Penn Medicine
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer
Barbara Ann Karmanos Cancer Institute
INCMGA00012 in Combination With Chemoradiation in Participants With Stage III Non-Small Cell Lung Cancer (POD1UM-301)
Incyte Corporation
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
Abramson Cancer Center at Penn Medicine
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
National Cancer Institute (NCI)
A Phase II Study of Neo-Adjuvant Gemcitabine, Cisplatin and Bevacizumab in Stage IIIA (N2) Non-Squamous Cell Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
HYPOLAN
The Netherlands Cancer Institute
Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer
Institut de Cancérologie de la Loire
Recombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLC
Zhejiang Cancer Hospital
High-dose ICE With Amifostine
Dana-Farber Cancer Institute
Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer
Hoosier Cancer Research Network
PROCLAIM
Eli Lilly and Company
The Efficacy and Safety of Apatinib Combined With Etoposide in Heavily Pretreated Advanced Non-small Cell Lung Cancer
Third Military Medical University
Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer
Hoosier Cancer Research Network
Proton Radiation Therapy With Cisplatin and Etoposide Followed by Surgery in Stage III Non-Small Cell Lung Cancer
Massachusetts General Hospital
Chemotherapy Plus Radiation Therapy With or Without Surgery in Treating Patients With Stage IIIA Non-small Cell Lung Cancer
Radiation Therapy Oncology Group
Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
University of Washington
Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer
Biotech Pharmaceutical Co., Ltd.
Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung
New Mexico Cancer Research Alliance
Stereotactic Boost for Locally Advanced Non-Small Cell Lung Cancer
Dana-Farber Cancer Institute
Radiation Therapy Plus Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
Radiation Therapy Oncology Group
Consolidation Chemotherapy/Concurrent Chemo-radiotherapy for Inoperable Stage III Non-small Cell Lung Cancer (NSCLC)
Louisiana State University Health Sciences Center Shreveport
Study of Sequential Topoisomerase, Irinotecan/Oxaliplatin - Etoposide /Carboplatin in Extensive Small Cell Lung Cancer (SCLC)
University of Alabama at Birmingham
Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd.
High-Dose Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Lung Cancer
National Cancer Institute (NCI)
S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors
SWOG Cancer Research Network
Combination Chemotherapy in Treating Patients With Stage I, II, or IIIA Non-small Cell Lung Cancer That Has Been Surgically Removed
National Cancer Institute (NCI)